Impact of Intravascular Imaging on Clinical Outcomes in Focal Versus Diffuse Coronary Artery Disease.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arai Taito, Sakai Koshiro, Ikeda Kazumasa, Mizukami Takuya, Bouisset Frédéric, Zhang Han, Matsumura Mitsuaki, Sonck Jeroen, Wilgenhof Adriaan, Matsuo Hitoshi, Amano Tetsuya, Ando Hirohiko, Hada Masahiro, Ko Brian, Biscaglia Simone, Rivero Fernando, Engstrøm Thomas, Leone Antonio Maria, van Nunen Lokien X, Fearon William F, Christiansen Evald Høj, Fournier Stephane, Desta Liyew, Yong Andy, Adjedj Julien, Escaned Javier, Nakayama Masafumi, Eftekhari Ashkan, Keulards Danielle, Zimmermann Frederik M, Korngold Ethan, Munhoz Daniel, Campo Gianluca, Berry Colin, Collison Damien, Johnson Thomas W, Perera Divaka, Jeremias Allen, Ali Ziad, De Bruyne Bernard, Mintz Gary S, Johnson Nils, Shinke Toshiro, Collet Carlos
Аннотация
METHODS: Prospective, multicenter, single-arm study of 811 patients (840 vessels) undergoing PCI. PPG was calculated from manual fractional flow reserve pullbacks to define focal (PPG ≥0.62) or diffuse coronary artery disease. IVI use was at the operator's discretion. The primary outcome was target vessel failure at 1-year follow-up.
RESULTS: IVI-guided PCI was performed in 41% of patients. In the overall cohort, target vessel failure was lower with IVI guidance (adjusted hazard ratio, 0.60 [95% CI 0.36-0.99]; P=0.044), with a lower incidence of cardiac death (P=0.042). IVI significantly reduced target vessel failure in focal disease (unadjusted HR, 0.41 [95% CI, 0.18-0.91]; P=0.029), whereas no difference was observed in diffuse disease (unadjusted HR, 0.91 [95% CI, 0.48-1.73]; P=0.771). There was no interaction between PPG and IVI guidance for target vessel failure (P for interaction=0.128).
CONCLUSIONS: In patients undergoing physiology-guided PCI, the use of IVI reduced clinical events at 1 year. These findings suggest that the benefit of IVI extends across the full spectrum of coronary artery disease.